Razan Awan: Large Cohort Study Questions Routine Use of Dual Antiplatelet Therapy After TAVI
ٌRazan Awan, Deputy Director of Residency Training Program at King Fahd Armed Forces Hospital, Cardiology Clinical Pharmacy Specialist, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Clinical Medicine, adding:
“Our new paper has just been published!
‘Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation.’
Journal of Clinical Medicine — Published June 5, 2026
In this work, we analyzed 662 consecutive TAVI patients without chronic anticoagulation to compare single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT).
Across multiple analytical models — including time-varying, intention-to-treat, landmark, and IPTW-weighted Cox analyses — no statistically significant difference was found between SAPT and DAPT in ischemic MACE (death, stroke, or MI) or net adverse clinical events.
These real-world findings support SAPT as a reasonable default antiplatelet strategy after TAVI, consistent with current ACC/AHA and ESC guidelines.
A special thank you to our lead author Monirah Albabtain, and corresponding author Amr Arafat, and to all co-authors for their incredible collaboration and dedication: Aisha Alrasheedi, Maha M. AlHarthi, Zaid Alanazi, and Nawaf Aldhubayti.”
Title: Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation
Authors: Monirah A. Albabtain, Aisha Alrasheedi, Razan M. Awan, Maha Alharthi, Zaid Alanazi, Nawaf Aldhubayti, Amr A. Arafat
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 11, 2026, 17:41Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?